FR2596990B1 - Adjuvant immunologique a base d'emulsion de lipide et d'un adjuvant bacterien - Google Patents

Adjuvant immunologique a base d'emulsion de lipide et d'un adjuvant bacterien

Info

Publication number
FR2596990B1
FR2596990B1 FR878705252A FR8705252A FR2596990B1 FR 2596990 B1 FR2596990 B1 FR 2596990B1 FR 878705252 A FR878705252 A FR 878705252A FR 8705252 A FR8705252 A FR 8705252A FR 2596990 B1 FR2596990 B1 FR 2596990B1
Authority
FR
France
Prior art keywords
adjuvant
bacterial
lipid emulsion
immunological
immunological adjuvant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
FR878705252A
Other languages
English (en)
French (fr)
Other versions
FR2596990A1 (fr
Inventor
John L Cantrell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ribi Immunochem Research Inc
Original Assignee
Ribi Immunochem Research Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ribi Immunochem Research Inc filed Critical Ribi Immunochem Research Inc
Publication of FR2596990A1 publication Critical patent/FR2596990A1/fr
Application granted granted Critical
Publication of FR2596990B1 publication Critical patent/FR2596990B1/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/5555—Muramyl dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • A61K2039/55594—Adjuvants of undefined constitution from bacteria

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
FR878705252A 1986-04-15 1987-04-14 Adjuvant immunologique a base d'emulsion de lipide et d'un adjuvant bacterien Expired - Lifetime FR2596990B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/852,120 US4806352A (en) 1986-04-15 1986-04-15 Immunological lipid emulsion adjuvant

Publications (2)

Publication Number Publication Date
FR2596990A1 FR2596990A1 (fr) 1987-10-16
FR2596990B1 true FR2596990B1 (fr) 1990-12-07

Family

ID=25312542

Family Applications (2)

Application Number Title Priority Date Filing Date
FR878705252A Expired - Lifetime FR2596990B1 (fr) 1986-04-15 1987-04-14 Adjuvant immunologique a base d'emulsion de lipide et d'un adjuvant bacterien
FR878705271A Expired - Lifetime FR2598622B1 (fr) 1986-04-15 1987-04-14 Adjuvants immunologiques pour vaccins polysaccharidiques

Family Applications After (1)

Application Number Title Priority Date Filing Date
FR878705271A Expired - Lifetime FR2598622B1 (fr) 1986-04-15 1987-04-14 Adjuvants immunologiques pour vaccins polysaccharidiques

Country Status (9)

Country Link
US (1) US4806352A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JPS6310736A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU574014B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA1300503C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (1) DE3712767A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (1) ES2005166A6 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FR (2) FR2596990B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
GB (1) GB2189141B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IT (1) IT1205819B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5916588A (en) * 1984-04-12 1999-06-29 The Liposome Company, Inc. Peptide-containing liposomes, immunogenic liposomes and methods of preparation and use
US6090406A (en) * 1984-04-12 2000-07-18 The Liposome Company, Inc. Potentiation of immune responses with liposomal adjuvants
CA1267087A (en) * 1985-02-14 1990-03-27 Nicolaas Visser Synthetic immunogen
DE3601136A1 (de) * 1986-01-16 1987-07-23 Max Planck Gesellschaft Hemmstoffe der reversen transkriptase fuer prophylaxe und therapie von retrovirus-infektionen in saeugetieren
US4803070A (en) * 1986-04-15 1989-02-07 Ribi Immunochem Research Inc. Immunological emulsion adjuvants for polysaccharide vaccines
US5554372A (en) * 1986-09-22 1996-09-10 Emory University Methods and vaccines comprising surface-active copolymers
US6054438A (en) * 1987-01-07 2000-04-25 Imperial Cancer Research Technology Limited Nucleic acid fragments encoding portions of the core protein of the human mammary epithelial mucin
US5466714A (en) * 1987-12-31 1995-11-14 Research Foundation For Mental Health Hygiene, Inc. Spermicidal and cytocidal fatty acid compositions
US4997851A (en) * 1987-12-31 1991-03-05 Isaacs Charles E Antiviral and antibacterial activity of fatty acids and monoglycerides
US5434182A (en) * 1987-12-31 1995-07-18 Isaacs; Charles E. Antibacterial fatty acid compositions
EP0324455A3 (en) * 1988-01-15 1991-03-27 Hans O. Ribi Novel polymeric immunological adjuvants
ES2019728A6 (es) * 1988-09-23 1991-07-01 Univ Southern California Procedimiento de preparacion de una vacuna de inmunoterapia para tumores de melanoma.
FI902821A7 (fi) * 1989-06-12 1990-12-13 Res Foundation For Mental Hygiene Infektion leviämisen vähentäminen verenkäsittelylaitteistolla
DE4007315A1 (de) * 1990-03-08 1991-09-12 Behringwerke Ag Verwendung von zink-calciumhydroxid, lecithin und pao zur adjuvierung von antigenloesungen und auf diese weise adjuvierte antigenloesungen
US5246707A (en) * 1990-04-26 1993-09-21 Haynes Duncan H Sustained release delivery of water-soluble bio-molecules and drugs using phospholipid-coated microcrystals, microdroplets and high-concentration liposomes
US5091188A (en) * 1990-04-26 1992-02-25 Haynes Duncan H Phospholipid-coated microcrystals: injectable formulations of water-insoluble drugs
HUT67762A (en) * 1991-03-19 1995-04-28 Cytrx Corp Polyoxypropylene/polyoxiethylene copolymers with improved biological activity and process for producing thereof
US5688761A (en) * 1991-04-19 1997-11-18 Lds Technologies, Inc. Convertible microemulsion formulations
AU668509B2 (en) * 1991-04-19 1996-05-09 Affinity Biotech, Inc. Convertible microemulsion formulations
IL105325A (en) * 1992-04-16 1996-11-14 Minnesota Mining & Mfg Immunogen/vaccine adjuvant composition
FR2702373B1 (fr) * 1993-03-08 1996-06-07 Rhone Merieux Emulsions vaccinales fluides eau-dans-l'huile contenant une huile métabolisable.
BR9405957A (pt) * 1993-03-23 1995-12-12 Smithkline Beecham Biolog Composições de vacina contendo lipidio A deacilatado 3-0 monofosforil
ATE246513T1 (de) * 1993-05-27 2003-08-15 Entremed Inc Zubereitungen und verfahren für die behandlung von krebs und hyperproliferierenden krankheiten
US5718904A (en) * 1995-06-02 1998-02-17 American Home Products Corporation Adjuvants for viral vaccines
US5690942A (en) * 1995-06-02 1997-11-25 American Home Products Corporation Adjuvants for viral vaccines
ATE386506T1 (de) * 1995-10-17 2008-03-15 Jagotec Ag Verabreichung unlöslicher arzneistoffe
US6465016B2 (en) 1996-08-22 2002-10-15 Research Triangle Pharmaceuticals Cyclosporiine particles
US7255877B2 (en) * 1996-08-22 2007-08-14 Jagotec Ag Fenofibrate microparticles
US5849307A (en) * 1997-03-26 1998-12-15 The Picower Institute For Medical Research Vaccine adjuvant
US6455323B1 (en) 1997-07-03 2002-09-24 Pharmacia & Upjohn Company Anti-bacterial methods and materials
CN1289091C (zh) * 1998-02-11 2006-12-13 Rtp药品公司 治疗炎症的药物组合物和相关用途
US6979456B1 (en) 1998-04-01 2005-12-27 Jagotec Ag Anticancer compositions
JP2002516267A (ja) 1998-05-29 2002-06-04 アールティーピー・ファーマ・インコーポレーテッド 熱的に保護された微粒子組成物及びその最終蒸気滅菌
HK1040195B (zh) 1998-08-19 2006-06-02 Skyepharma Canada Inc. 普鲁泊福的可注射水分散体
GB2348203B (en) 1998-11-04 2002-06-19 Imp College Innovations Ltd Solube beta-forms of prion proteins, methods of preparation and use
AU767154B2 (en) 1998-11-20 2003-10-30 Skyepharma Canada Inc. Dispersible phospholipid stabilized microparticles
EP2281833B1 (en) 1999-04-09 2014-07-02 Zoetis P&U LLC Attenuated Pasteurellaceae bacterium having a mutation in a virulence gene
US6790950B2 (en) 1999-04-09 2004-09-14 Pharmacia & Upjohn Company Anti-bacterial vaccine compositions
JP2003509453A (ja) * 1999-09-21 2003-03-11 アールティーピー・ファーマ・インコーポレーテッド 生物学的に活性な物質の、表面改質された粒状組成物
AU2001256957B2 (en) 2000-03-17 2005-08-25 Pharmacia & Upjohn Company Llc Salmonella vaccine materials and methods
WO2001077365A2 (en) 2000-04-06 2001-10-18 Pharmacia & Upjohn Company Antimicrobial methods and materials
AU5711501A (en) 2000-04-20 2001-11-07 Rtp Pharma Inc Improved water-insoluble drug particle process
US7323174B1 (en) 2000-06-12 2008-01-29 Arizona Board Of Regents On Behalf Of The University Of Arizona Modulation of immune response and methods based thereon
NZ525028A (en) 2000-08-31 2005-07-29 Skyepharma Canada Inc Milled particles
US8586094B2 (en) * 2000-09-20 2013-11-19 Jagotec Ag Coated tablets
JP2004509146A (ja) * 2000-09-20 2004-03-25 スカイファーマ・カナダ・インコーポレーテッド 安定化フィブレート微粒子
TWI288000B (en) * 2001-02-22 2007-10-11 Rtp Pharma Inc Fibrate-statin combinations with reduced fed-fasted effects
FR2824279B1 (fr) * 2001-05-04 2004-05-28 Seppic Sa Emulsion e/h concentree
GB0112126D0 (en) 2001-05-18 2001-07-11 Allergene Inc Composition
FR2824269B1 (fr) * 2001-09-03 2012-03-02 Seppic Sa Composition adjuvante constituee de 1% a 15% de tensioactifs a hlb global compris entre 5 et 8 et de 85% a 99% de corps gras
US8193185B2 (en) 2003-01-21 2012-06-05 Novartis Vaccines And Diagnostics, Inc. Use of tryptanthrin compounds for immune potentiation
EP1608369B1 (en) 2003-03-28 2013-06-26 Novartis Vaccines and Diagnostics, Inc. Use of organic compounds for immunopotentiation
GB0315323D0 (en) 2003-07-01 2003-08-06 Royal Veterinary College Vaccine composition
US9023366B2 (en) 2003-07-01 2015-05-05 The Royal Veterinary College Vaccine composition for vaccinating dogs against canine infectious respiratory disease (CIRD)
US20110104186A1 (en) 2004-06-24 2011-05-05 Nicholas Valiante Small molecule immunopotentiators and assays for their detection
EP2277595A3 (en) 2004-06-24 2011-09-28 Novartis Vaccines and Diagnostics, Inc. Compounds for immunopotentiation
US20060210590A1 (en) 2005-02-03 2006-09-21 Alk-Abello A/S Minor allergen control to increase safety of immunotherapy
ATE539079T1 (de) * 2006-03-23 2012-01-15 Novartis Ag Imidazochinoxalinverbindungen als immunmodulatoren
WO2007109810A2 (en) * 2006-03-23 2007-09-27 Novartis Ag Methods for the preparation of imidazole-containing compounds
ES2388556T3 (es) * 2006-03-23 2012-10-16 Novartis Ag Compuestos inmunopotenciadores
US9498493B2 (en) 2007-09-27 2016-11-22 Immunovaccine Technologies Inc. Use of liposomes in a carrier comprising a continuous hydrophobic phase for delivery of polynucleotides in vivo
US20100209452A1 (en) * 2007-10-03 2010-08-19 Immunovaccine Technologies, Inc Compositions comprising an antigen, an amphipathic compound and a hydrophobic carrier, and uses thereof
EP2296696B1 (en) 2008-06-05 2014-08-27 ImmunoVaccine Technologies Inc. Compositions comprising liposomes, an antigen, a polynucleotide and a carrier comprising a continuous phase of a hydrophobic substance
AP2011005745A0 (en) 2008-12-09 2011-06-30 Gilead Sciences Inc Modulators of toll-like receptors.
WO2011092846A1 (ja) 2010-01-29 2011-08-04 株式会社 ミキモト 装身具用クラスプ
SI2569008T1 (sl) 2010-05-14 2020-02-28 Baxalta Incorporated Himere OSPA in njihova uporaba v cepivih
WO2012010290A1 (en) 2010-07-21 2012-01-26 Athera Biotechnologies Ab Diagnostic and therapeutic methods and compositions for metabolic disease
WO2012010291A1 (en) 2010-07-21 2012-01-26 Athera Biotechnologies Ab Diagnostic and therapeutic methods and compositions for metabolic disease
EP2462950A1 (en) 2010-12-08 2012-06-13 Neovacs Strongly inactivated and still highly immunogenic vaccine, and process of manufacturing thereof
RU2013125147A (ru) 2010-12-08 2015-01-20 Неовакс Сильно инактивированная иммуногенная вакцина, сохраняющая высокую иммуногенность, и способ ее изготовления
EP2694094B1 (en) 2011-04-07 2017-08-16 Neovacs METHOD FOR TREATING IFNalpha RELATED CONDITIONS
EP2508197A1 (en) 2011-04-07 2012-10-10 Neovacs Method for treating IFNalpha related conditions
ES2855474T3 (es) 2011-10-06 2021-09-23 Immunovaccine Technologies Inc Composiciones de liposomas que comprenden un adyuvante que activa o incrementa la actividad de TLR2 y usos del mismo
GB201200259D0 (en) 2012-01-09 2012-02-22 Ohlin Per M Novel therapies
RU2015106742A (ru) 2012-07-27 2016-09-20 Бакстер Интернэшнл Инк. Композиции, содержащие химерные молекулы ospa и способы их применения
WO2016001907A1 (en) 2014-07-02 2016-01-07 Prendergast Patrick T Mogroside iv and mogroside v as agonist/stimulator/un-blocking agent for toll-like receptor 4 and adjuvant for use in human/animal vaccine and to stimulate immunity against disease agents.
US11725044B2 (en) 2014-10-15 2023-08-15 Xenothera Method for producing polyclonal antibodies with improved complement-dependent cytotoxicity
EP3801628A1 (en) 2018-06-04 2021-04-14 Apros Therapeutics, Inc. Tlr7 peptide conjugates
KR20210027381A (ko) 2018-07-02 2021-03-10 아유비스 리서치, 인코포레이티드 신규 면역조절 소분자
EP3922255A1 (en) 2020-06-10 2021-12-15 Prokarium Limited Cancer therapy
GB202009411D0 (en) 2020-06-19 2020-08-05 Prokarium Ltd Autotransporter systems
CN112807426A (zh) * 2021-01-26 2021-05-18 郭志文 一种基于动物疫苗的聚合物佐剂、制备方法及其应用
EP4124342A1 (en) 2021-07-28 2023-02-01 Prokarium Limited Cancer therapy with live attenuated bacteria
EP4399219A1 (en) 2021-09-07 2024-07-17 Université de Tours Coronavirus fusion protein
GB202215134D0 (en) 2022-10-13 2022-11-30 Prokarium Ltd Composition
GB202215576D0 (en) 2022-10-21 2022-12-07 Prokarium Ltd Circuit
WO2025068413A1 (en) 2023-09-28 2025-04-03 Prokarium Limited Interleukin 18 variants
WO2025068401A1 (en) 2023-09-28 2025-04-03 Prokarium Limited Interleukin 15 variant
WO2025109155A1 (en) 2023-11-24 2025-05-30 Prokarium Limited Interleukin variant

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1163470A (en) * 1967-11-13 1969-09-04 Cecil Arthur Clark Improvements in or relating to Adjuvant Vaccines
CA943459A (en) * 1968-12-16 1974-03-12 Abbott Laboratories Chemically modified endotoxin immunizing agent
FR2160326B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) * 1971-11-19 1975-02-07 Anvar
US4185090A (en) * 1972-02-02 1980-01-22 Abbott Laboratories Chemically modified endotoxin immunizing agent
GB1506563A (en) * 1974-04-25 1978-04-05 Williams J Immunosuppressive agents
FR2313078A1 (fr) * 1975-02-07 1976-12-31 Anvar Composition a base d'huile vegetale metabolisable et d'eau, utilisable notamment pour la constitution de preparations adjuvantes, ces preparations adjuvantes et leur procede d'obtention
US4338334A (en) * 1977-12-29 1982-07-06 Merck & Co., Inc. 1-[4-(4-Sulfanilyl)phenyl] urea and derivatives in compositions and methods of treating rheumatoid arthritis and immune complex diseases
US4307229A (en) * 1979-11-07 1981-12-22 Avraham Liav 6,6'-Diesters of trehalose and process for the synthesis thereof
US4436727A (en) * 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4436728A (en) * 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4606918A (en) * 1983-08-22 1986-08-19 Syntex (U.S.A.) Inc. Polyoxypropylene-polyoxyethylene block polymer based adjuvants
CA1225592A (en) * 1983-08-26 1987-08-18 Ribi Immunochem Research Inc. Refined detoxified endotoxin
US4663306A (en) * 1983-09-23 1987-05-05 Ribi Immunochem Research, Inc. Pyridine-soluble extract-refined detoxified endotoxin composition and use
JPH077201B2 (ja) * 1985-10-19 1995-01-30 富士写真フイルム株式会社 ハロゲン化銀カラ−写真感光材料の処理方法

Also Published As

Publication number Publication date
FR2598622A1 (fr) 1987-11-20
DE3712767C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1991-06-27
AU7156687A (en) 1987-10-22
US4806352A (en) 1989-02-21
GB2189141A (en) 1987-10-21
IT1205819B (it) 1989-03-31
GB2189141B (en) 1990-07-25
FR2598622B1 (fr) 1990-05-11
ES2005166A6 (es) 1989-03-01
DE3712767A1 (de) 1987-10-22
JPH041728B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1992-01-14
JPS6310736A (ja) 1988-01-18
FR2596990A1 (fr) 1987-10-16
CA1300503C (en) 1992-05-12
GB8709023D0 (en) 1987-05-20
AU574014B2 (en) 1988-06-23
IT8747855A0 (it) 1987-04-15

Similar Documents

Publication Publication Date Title
FR2596990B1 (fr) Adjuvant immunologique a base d'emulsion de lipide et d'un adjuvant bacterien
IT8968042A0 (it) Giunto cardanico a rapporto di velocita' costante
DE68928739D1 (de) Detecteur d'humidite
FR2591674B1 (fr) Dispositif de reglage des jeux radiaux entre rotor et stator d'un compresseur
IT1217948B (it) Giunto a velocita' costante
FR2609638B1 (fr) Plancher d'entrainement
AU7609387A (en) Chagas' disease antigen
IT9020734A0 (it) dispositivo d'aspirazione
FR2523447B1 (fr) Preparation therapeutiques entimycotiques a base de creme et d'onguent
FR2593492B1 (fr) Rembourrage d'oreiller
BR1100939A (pt) Conjugado veìculo-droga e conjugado proteìna-droga
FR2619174B1 (fr) Element d'accouplement d'arbre
TR22839A (tr) Suebstituee edilmis belirli 3-(suebstituee oksi)-2-benzolysikloheksk 2-enon'lar
FR2632428B1 (fr) Processeur d'image
DK482488D0 (da) 3'-demethoxyepipodophyllotoxinglucosidderivater
FR2594057B3 (fr) Dispositif d'encochage
FR2634428B1 (fr) Regulateur d'embrayage
FR2616054B1 (fr) Meuble pliant pourvu d'un pietement en " x "
KR880013319U (ko) 브이씨알의 클러치장치
FR2576214B1 (fr) Compositions pharmaceutiques a base de diltiazem et d'un antihypertenseur
FR2605440B1 (fr) Dispositif d'affichage ge
KR890005249U (ko) 벤티레이타 (Ventilatort) 의 샤후트 (Shaft) 장치
KR910003277U (ko) 브이 씨 알의 슬랜트 베이스 조립체
RO93443A2 (ro) Emolient textil pe baza de esteramine
KR880007682U (ko) 시머기의 클러치장치